Stock research log
$SMMT Insider Trading
Summit Therapeutics Inc.
11
Alerts Listed
0
Insider Buys 30d
0
Insider Sells 30d
This page is InsiderWatch’s research log for SMMT: the alerts we sent on this stock, timestamped, plus recent insider buying and selling reported to the SEC on Form 4.
Price and Our Alerts
$SMMT price
Daily closing prices
3M change
+9.8%
1Y high
$26.38
1Y low
$12.43
Our alerts
11
in this window
Prices from public market data and may be delayed. Markers show the days our alerts on this stock fired. Not investment advice.
Our Alerts on $SMMT
| Sent (ET) | Call | Alert |
|---|---|---|
| Oct 25, 11:34 AM | NEUTRAL | Ivonescimab beats durvalumab on survival in bile-duct cancer |
| Oct 1, 6:39 PM | NEUTRAL | AstraZeneca's $2B Summit deal expands ivonescimab trials |
| Sep 29, 9:55 AM | NEUTRAL | AstraZeneca invests $2B in Summit Therapeutics cancer program |
| Sep 14, 8:42 AM | NEUTRAL | Summit's ivonescimab beats Keytruda in pivotal data |
| Sep 13, 7:14 AM | BULLISH | Summit's ivonescimab beats Keytruda on survival in lung cancer |
| Sep 8, 9:52 PM | BULLISH | Summit's ivonescimab beats Keytruda on survival in Phase 3 |
| Sep 7, 2:12 AM | NEUTRAL | Summit Therapeutics up 28% on ivonescimab survival data |
| Sep 4, 11:06 AM | NEUTRAL | Summit's ivonescimab beats Keytruda on survival |
| Sep 2, 5:02 PM | BULLISH | Akeso's ivonescimab beats Keytruda on survival in Phase III |
| Aug 26, 11:32 PM | NEUTRAL | Summit rises on positive Phase III biliary cancer data |
| Aug 25, 6:17 PM | BULLISH | Summit's ivonescimab hits survival goal in Phase III cancer trial |
Every alert we sent on SMMT is listed after a short delay, in the order it went out. The call shown is the one in the alert as sent.
See the research log across all stocks, this week’s insider buying, or the congress trading tracker.
Get the Next SMMT Alert When It Fires.
Everything here is already public. Subscribers usually got it within minutes. Pro members get every alert. Free for 7 days, cancel any time.
Try Free for 7 DaysInsiderWatch is an informational research service based on publicly available information only and is not financial, investment, legal, or tax advice. The call shown is a reading of the event, not a recommendation to trade.